MktsMarkets

Tempest Therapeutics, Inc.
NASDAQ: TPSTKey statistics
TPST News
Stories mentioning TPST from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (27,719) | (4,076) | (3,597) | (7,966) | (10,936) | (13,919) | (10,551) | (9,582) |
| Interest Income | ||||||||
| Interest Expense | 372.00 | |||||||
| Other Expense | 23.00 | 55.00 | 86.00 | 142.00 | 237.00 | 353.00 | 324.00 | 384.00 |
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | (27,696) | (4,021) | (3,511) | (7,870) | (10,860) | (13,813) | (10,556) | (9,570) |
| Earnings Per Share (Basic) | (2.53) | (0.97) | (0.79) | (2.07) | (3.16) | (6.44) | (5.32) | (5.52) |
| Earnings Per Share (Diluted) | (2.53) | (0.97) | (0.79) | (2.07) | (3.16) | (6.44) | (5.32) | (5.52) |
| Weighted Average Shares Outstanding (Basic) | 10,932 | 4,150 | 4,440 | 3,803 | 3,438 | 2,146 | 1,985 | 1,734 |
| Weighted Average Shares Outstanding (Diluted) | 10,932 | 4,150 | 4,440 | 3,803 | 3,438 | 2,146 | 1,985 | 1,734 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TPST
Tempest Therapeutics, Inc. (NASDAQ: TPST) is a stock listed on the Nasdaq Stock Market under the ticker symbol TPST. It last traded at $0.5000 (Oct 30, 2026, 4:00 PM ET), down 7.1% on the day. That gives Tempest Therapeutics a market capitalisation of $10.7M.
Over the past 52 weeks TPST has traded between $0.5000 and $10.93.
For the quarter ended Mar 31, 2026 it reported a net loss of $27.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$27.7M |
| Dec 31, 2025 | — | -$4.0M |
| Sep 30, 2025 | — | -$3.5M |
| Jun 30, 2025 | — | -$7.9M |
From Tempest Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…